To Evaluate The Efficacy Of Intravenous Selenium Administration In Critically Ill Patients

Abstract

Listen

Translate article

Sepsis and systemic inflammatory response syndrome continue to be leading causes of death in critically ill patients. These conditions are characterized by elevated oxidative stress and diminished levels of antioxidants. Selenium (Se), a micronutrient, plays crucial roles in antioxidation, inflammation suppression, and immune function, making it pivotal in combating oxidative stress and supporting overall health in such patients. This study aims to assess the impact of intravenous selenium supplementation on sequential organ failure assessment score (SOFA) and to investigate selenium's potential as a biomarker in critically ill patients. Patients and Methods: Fifty-five critically ill patients received intravenous Se at a dosage of 600 micrograms daily for three consecutive days. Clinical parameters including SOFA score, ICU and hospital stays, and duration of mechanical ventilation and biochemical parameters such as C-reactive protein (CRP), Interleukin-6 (IL 6), Se levels, and total leukocyte count (TLC) were assessed before Se administration and on the fifth day post-administration for analysis. Results: After administering Se injections, there was a significant increase in serum Se concentrations from 195.45±64.03 to 295.45±87.81 "p <0.001". Additionally, a notable decrease in SOFA score was observed, dropping from 7.21 to 6.41 "p = 0.004". Furthermore, CRP levels showed a statistically significant decrease following Se administration. Conclusions: Our study findings demonstrate significant improvements in SOFA score and CRP levels among the patients. Se supplementation significantly boosts plasma Se levels, thereby enhancing tissue Antioxidant Capacity inThese Patients